← Back to screener

Amneal Pharmaceuticals, Inc. AMRX

Rank #1263 · Nasdaq · $6.9B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
51.0
P/E
-81.7
P/B
-62.80
ROE
76.9%
Op. Margin
8.5%
Debt Ratio
-3304%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -81.7x, P/B -62.80x. Ranks in the top 84% of the universe.

Profitability ★★★★☆
Good

ROE 76.9%. Ranks in the top 26% of the universe.

Safety ★★★★★
Excellent

Debt ratio -3304%. Ranks in the top 1% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Good

Revenue growth of 8.2% year over year. Ranks in the top 39% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2017–––$0.0B––
2018$1.0B$0.3B$0.0B$0.5B28.0166
2019$1.0B$0.2B$0.0B$0.5B23.7762
2020$1.7B$-0.0B$-0.0B$0.2B-1.21480
2021$1.6B$-0.2B$-0.6B$0.3B-15.31221
2022$2.0B$0.1B$0.1B$0.4B4.6993
2023$2.1B$0.2B$0.0B$0.3B7.31173
2024$2.2B$-0.1B$-0.3B$0.0B-4.317455
2025$2.4B$0.2B$-0.1B$-0.1B8.5-3304

← See the full screener